Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Prognostic Significance of Initial PSMA PET/CT Imaging for Survival Outcomes in Synchronous Metastatic Hormone-Sensitive Prostate Cancer: A Shift in Understanding Low- versus High-Volume Disease

  • By

  • Fleur Kleiburg

  • Linda Heijmen

  • Annemieke Witteveen

  • Kiki van Duuren

  • Paul Zuidgeest

  • Frits Smit

  • Lioe-Fee de Geus-Oei

  • Tom van der Hulle

  • September 16, 2026

Share

  • 1

    Androgen deprivation therapy (ADT) remains the primary treatment for metastatic hormone-sensitive prostate cancer (mHSPC).

  • 2

    PSMA PET/CT imaging has replaced conventional imaging due to its superior sensitivity and accuracy in detecting metastases.

  • 3

    The CHAARTED trial established low-volume and high-volume disease classifications that influence treatment decisions for mHSPC patients.

  • 4

    This study aims to revise risk stratification for mHSPC patients using PSMA PET/CT data to inform personalized treatment decisions.

  • 5

    Overall survival and PSA progression-free survival are the primary endpoints measured from the initiation of ADT in this study.

Original Source(s)

Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease

  • by Fleur Kleiburg, Linda Heijmen, Annemieke Witteveen, Kiki van Duuren, Paul Zuidgeest, Frits Smit, Lioe-Fee de Geus-Oei, Tom van der Hulle

  • September 16, 2026

Related Content

AI-Designed Binder Improves CAR T Cell Activity in Mice

Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control

  • September 15, 2026

  • 3 min
Musings from The Power List: Dajun Yang

The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics

  • September 15, 2026

  • 5 min
Cost-Effectiveness of Smoking Cessation Interventions Integrated Into Lung Cancer Screening